Trials / Completed
CompletedNCT02244827
Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment
A Phase I, Open Label, Single Dose Study to Evaluate The Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Wockhardt · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This study is aimed to compare the pharmacokinetics of levonadifloxacin and its sulfate metabolite after a single dose of oral WCK 2349 1000 mg in patients with hepatic impairment and healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | WCK 2349 | levonadifloxacin (active drug) and the sulfate metabolite |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2014-12-01
- Completion
- 2015-06-01
- First posted
- 2014-09-19
- Last updated
- 2015-10-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02244827. Inclusion in this directory is not an endorsement.